全文获取类型
收费全文 | 253527篇 |
免费 | 50589篇 |
国内免费 | 5025篇 |
专业分类
耳鼻咽喉 | 2968篇 |
儿科学 | 7327篇 |
妇产科学 | 2183篇 |
基础医学 | 49158篇 |
口腔科学 | 9761篇 |
临床医学 | 22821篇 |
内科学 | 46667篇 |
皮肤病学 | 6586篇 |
神经病学 | 30440篇 |
特种医学 | 9033篇 |
外国民族医学 | 43篇 |
外科学 | 25914篇 |
综合类 | 16588篇 |
现状与发展 | 22篇 |
一般理论 | 8篇 |
预防医学 | 14058篇 |
眼科学 | 2969篇 |
药学 | 30853篇 |
39篇 | |
中国医学 | 7006篇 |
肿瘤学 | 24697篇 |
出版年
2024年 | 449篇 |
2023年 | 2814篇 |
2022年 | 6192篇 |
2021年 | 8358篇 |
2020年 | 11302篇 |
2019年 | 16505篇 |
2018年 | 15934篇 |
2017年 | 16889篇 |
2016年 | 15576篇 |
2015年 | 16354篇 |
2014年 | 18775篇 |
2013年 | 19800篇 |
2012年 | 17736篇 |
2011年 | 19135篇 |
2010年 | 15950篇 |
2009年 | 12864篇 |
2008年 | 13087篇 |
2007年 | 10653篇 |
2006年 | 9513篇 |
2005年 | 8605篇 |
2004年 | 7817篇 |
2003年 | 6932篇 |
2002年 | 5852篇 |
2001年 | 4670篇 |
2000年 | 3362篇 |
1999年 | 2147篇 |
1998年 | 1891篇 |
1997年 | 1818篇 |
1996年 | 1640篇 |
1995年 | 1567篇 |
1994年 | 1397篇 |
1993年 | 1278篇 |
1992年 | 1035篇 |
1991年 | 932篇 |
1990年 | 818篇 |
1989年 | 682篇 |
1988年 | 622篇 |
1987年 | 603篇 |
1986年 | 702篇 |
1985年 | 1028篇 |
1984年 | 1065篇 |
1983年 | 775篇 |
1982年 | 811篇 |
1981年 | 664篇 |
1980年 | 602篇 |
1979年 | 477篇 |
1978年 | 322篇 |
1977年 | 274篇 |
1976年 | 285篇 |
1975年 | 191篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
21.
Rosario Gulias-Cañizo Anell Lagunes-Guillén Arturo González-Robles Erika Sánchez-Guzmán Federico Castro-Muñozledo 《Burns : journal of the International Society for Burn Injuries》2019,45(2):398-412
Background
Since recent reports have shown that (-)-Epigallocatechin-3-gallate (EGCG) could be used for treating proliferative and inflammatory disorders, we explored its use for the management of corneal chemical burns.Materials and methods
Initially, EGCG was assayed on the rabbit corneal epithelial cell line RCE1(5T5) to establish the best testing conditions, and to avoid unwanted outcomes in the experimental animals. Then, we studied its effects on cell proliferation, cell cycle progression and cell differentiation. Afterwards, we instilled EGCG in experimental grade II corneal alkali burns in mice, three times a day up to 21 days, and evaluated by slit lamp examination and histological sections of corneal epithelial, corneal endothelial and stromal edema, as well as the presence of inflammatory cells and neovascularization.Results
EGCG reduced cell growth and led to a decline in the proportion of proliferative cells in a concentration dependent manner. At 10 μM, EGCG promoted cell differentiation, an effect not related with apoptosis or cytotoxicity. When 10 μM EGCG was instilled in corneal alkali burns in mice three times a day up to 21 days, EGCG significantly reduced corneal opacity and neovascularization. The improved clinical appearance of the cornea was associated to a controlled epithelial growth; epithelial morphology was similar to that observed in normal epithelium and contrasted with the hyperproliferative, desquamating epithelium observed in control burn wounds. EGCG reduced corneal, stromal and endothelial edema, and wound inflammation.Conclusion
This work constitutes the first evidence for the use of EGCG in the acute phase of a corneal alkali burn, representing a possible novel alternative to improve patient outcomes as an add-on therapy. 相似文献22.
23.
《Mayo Clinic proceedings. Mayo Clinic》2019,94(7):1321-1329
Immune checkpoint inhibitors are molecules that increase the endogenous immune response against tumors. They have revolutionized the field of oncology. Since their initial approval for the treatment of advanced melanoma, their use has expanded to the treatment of several other advanced cancers. Unfortunately, immune checkpoint inhibitors have also been associated with the emergence of a new subset of autoimmune-like toxicities, known as immune-related adverse events. These toxicities differ depending on the agent, malignancy, and individual susceptibilities. Although the skin and colon are most commonly involved, any organ may be affected, including the liver, lungs, kidneys, and heart. Most of these toxicities are diagnosed by excluding other secondary infectious or inflammatory causes. Corticosteroids are commonly used for treatment of moderate and severe immune-related adverse events, although additional immunosuppressive therapy may occasionally be required. The occurrence of immune-related toxicities may require discontinuation of immunotherapy, depending on the specific toxicity and its severity. In this article, we provide a focused review to familiarize practicing clinicians with this important topic given that the use of immune checkpoint inhibitors continues to increase. 相似文献
24.
25.
26.
PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease 下载免费PDF全文
27.
28.
29.
《Clinical genitourinary cancer》2022,20(3):e217-e226
Background: Intraductal carcinoma and cribriform (IDC/C) tumor features are well-established prognosticators of biochemical recurrence (BCR), metastasis, and prostate cancer (PCa)-specific mortality. However, approximately 70% of PCa patients undergoing a radical prostatectomy are IDC/C negative, yet up-to 20% of these patients progress and experience BCR. Thus, tumor histopathologic characteristics such as IDC/C alone are limited in their ability to predict disease progression. Conversely, several nomograms such as Cancer of the Prostate Risk Assessment-Surgery (CAPRA-S) have been developed to aid in the prognostication of BCR, but not yet widely applied in clinical settings. Materials and methods: In this study, we assessed the combined prognostic utility of IDC/C, and CAPRA-S for BCR in 3 PCa patient cohorts. Results: CAPRA-S+IDC/C improved the predictive accuracy of BCR in all 3 cohorts (P < .001). Specifically, among IDC/C negative cases, CAPRA-S improved the prognostication of BCR in low-risk (Cohort 1; P < .001, Cohort 2; P < .001, Cohort 3; P = .003), intermediate (Cohort 1; P < .001, Cohort 2; P = .006, Cohort 3; P = .03) and high-risk (Cohort 1-3; P < .001) patients. Conversely, IDC/C improved the prognostication of BCR among CAPRA-S low-risk (Cohorts 1; P < .001 and Cohort 3; P = .003) patients. Conclusion: Our results suggest the investigation of histopathological IDC/C features in CAPRA-S low-risk patients and conversely, nomogram CAPRA-S among IDC/C negative patients improves the identification of patients likely to experience BCR, which would otherwise be missed through current assessment regimens. These patients can be offered more intensive monitoring and adjuvant therapies upfront to circumvent the development of recurrent cancer or overtreatment at the time of surgery. 相似文献
30.